Delivery Order SPE2DB24D2205-SPE2DB24FDUWM

Award Date 5/30/24
Potential Completion Date 5/31/24
Potential Value $36K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,906.12, is for the supply of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product. The contract is a firm fixed-price delivery order with a completion date of July 16, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,423.20, is for the supply of CONTRAVE ER 8-90 MG TABLET 120S, a prescription medication. The contract has a completion date of July 16, 2024 and is a firm fixed-price contract. AmerisourceBergen, a for-profit organization, is the prime contractor and there is no set-aside designation for...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $18,709.96 with a firm fixed price, for the delivery of CONTRAVE ER 8-90 MG TABLET 120S. The contract has an ultimate completion date of March 24, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,063.16, is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product. The contract has a firm fixed price and an ultimate completion date of May 31, 2024. This contract is not designated as a set-aside. Amerisourcebergen holds a significant...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of CONTRAVE ER 8-90 MG TABLET 120S. The contract has a firm fixed price of $2,082.65 and an ultimate completion date of October 18, 2024. The award is not associated with a set-aside program. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,082.38, is for the delivery of Contrave ER 8-90 mg tablets. The contract has a period of performance through March 4, 2024 and utilizes a firm fixed-price pricing structure. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $43,778.54 firm-fixed-price contract is for the supply of CONTRAVE ER 8-90 MG TABLET 120S, a prescription medication. The contract has an ultimate completion date of August 6, 2024 and was awarded on August 5, 2024. This contract is not set aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of CONTRAVE ER 8-90 mg tablets. The award, valued at $23,339.77, has an ultimate completion date of August 13, 2024. The contract is a firm fixed-price delivery order without a set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,973.74 firm fixed-price contract is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product, with a performance period through May 9, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,819.47, is for the delivery of CONTRAVE ER 8-90 MG TABLET 120S, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of February 12, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
  • SPE2DB24D2205
    Indefinite Delivery Contract
  • SPE2DB24D2205-SPE2DB24FDUWM
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $35,904.99, is for the provision of CONTRAVE ER 8-90 MG TABLET 120S, a medication. The contract has a firm fixed price and is set to expire on May 31, 2024. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 5/16/25, 12:30 PM